NASHVILLE DEPO-PROVERA MENINGIOMA LAWYER
TIMOTHY L. MILES
(855) TIM-M-LAW (855-846-659)
(24/7/365)
New studies show a startling 53% increased risk of Meningioma linked to injectable medroxyprogesterone acetate (MPA), the active ingredient in Depo-Provera. Our team of Depo-Provera Meningiomas Lawyers has tracked these developments since the birth control shot got U.S. Food and Drug Administration (FDA) approval in October 1992.
Patients receive Depo-Provera shots every three months. The drug comes in two forms: a 150 mg intramuscular injection and Depo-SubQ Provera 104, a 104 mg subcutaneous injection approved in 2004. The drug carries a black box warning that advises against use beyond two years because it can cause bone density loss. A newer study, published in 2024 by The BMJ strengthened the connection between Depo-Provera and meningioma, especially with long-term use.
The researchers looked at 108,366 women and found that 18,061 needed surgery for meningioma between 2009 and 2018. Depo-Provera lawsuit lawyers now represent patients who seek compensation, since meningiomas make up 40% of primary central nervous system tumors. A meningioma Depo-Provera specialist or a Nashville Depo-Provera meningioma attorney can help you learn if you qualify to take legal action against manufacturer Pfizer.
Recent medical evidence a stronger link between Depo-Provera and meningioma based on two groundbreaking studies from 2024. A detailed study in Cancers looked at 117,503 meningioma cases compared to 1,072,907 matched controls. The results showed injectable medroxyprogesterone acetate (MPA) increased the risk of developing meningiomas by 53%. The risk grew higher with longer use.
The BMJ published another study in March 2024 that supports these findings. They studied 108,366 women in France, with 18,061 who needed surgery for meningioma. The results were concerning – women who used injectable medroxyprogesterone acetate had a 5.55 times higher risk of developing intracranial meningiomas than those who didn’t use it.
The risk increases based on how long you use it:
The research showed this higher risk applies to cerebral meningiomas but not spinal meningiomas. The numbers tell an important story – MPA exposure was nearly twice as high in meningioma cases (0.67%) compared to controls (0.39%).
The researchers found that five out of 10,000 women using medroxyprogesterone acetate might develop meningioma. This is a big deal as it means that only one out of 10,000 non-users face the same risk. French health authorities raised concerns about high-dose progestin contraceptives back in 2019.
The science behind this makes sense. Meningiomas have progesterone receptors that create a pathway for tumors to grow when exposed to synthetic progesterone like MPA. The medical data suggests you need to treat 2,300 individuals with medroxyprogesterone to see one case of meningioma.
These findings matter even more because Depo-Provera is popular – up to 25% of sexually active women between 18-49 in the United States use it. This research provides vital scientific evidence that Depo-Provera lawsuit lawyers can use to prove causation in legal cases for meningioma Depo-Provera patients seeking justice.
Pfizer faces multiple lawsuits in 2025 because they did not tell US patients about critical meningioma warnings. The company updated warning labels about this life-altering side effect in Europe, Canada, and other countries, yet US drug labels still lack this crucial information.
These legal claims rest on “failure to warn” – the life-blood of the argument that manufacturers must tell doctors and patients about known risks. Evidence suggests Pfizer knew about the meningioma-Depo-Provera connection since 1983, well before FDA approval. European labels clearly state that “meningiomas have been reported following long-term administration of progestogens”. US labels show no such warning through July 2024.
Pfizer told the Judicial Panel on Multidistrict Litigation (JPML) in January 2025 that FDA denied their request to add a meningioma warning. In spite of that, lawsuits argue Pfizer could have updated warnings through the “Changes Being Effected” process without waiting for FDA approval.
Florida federal court currently handles about 130 Depo-Provera lawsuits. Plaintiffs must meet these requirements:
Depo-Provera meningioma attorneys fight for compensation covering:
Settlement values for a Depo-Provera lawsuit typically range from $100,000 to $500,000 based on case details. Lawyers expect higher amounts for severe cases with multiple surgeries or permanent disabilities.
State laws set different time limits, usually 2-3 years from diagnosis or when patients connect their condition to Depo-Provera. Quick consultation with a Depo-Provera meningiomas injury lawyer becomes crucial.
Recent landmark studies have made the link between Depo-Provera and meningioma risk much stronger. The 2024 research shows a 53% higher risk, which is a big deal as it means that patients and healthcare providers need to be extra careful. Women who use injectable medroxyprogesterone acetate face 5.55 times higher risk than non-users when they use it for a long time.
The science behind this makes sense. Meningiomas have lots of progesterone receptors, and that’s how this contraceptive might cause tumors to grow. The genetic makeup of progestin-related meningiomas, especially those with PIK3CA mutations, makes the cause-and-effect relationship even clearer.
Pfizer hasn’t updated US warning labels yet, even though Europe and Canada already have these warnings in place. This gap in warning labels is the life-blood of about 130 Depo-Provera lawsuits now in Florida federal court. Anyone who developed meningiomas after using Depo-Provera should think about their legal rights and pursuing a Depo-Provera lawsuit,
Women who’ve used Depo-Provera for a long time need to know the signs of meningioma. These include headaches, vision changes, seizures, and other neurological problems. Quick medical help can lead to early diagnosis if you notice anything wrong. We’re keeping track of both scientific findings and legal cases about this contraceptive, hoping everyone gets better safety information soon.
Q1. What is the link between Depo-Provera and meningioma risk? Recent studies have shown that using Depo-Provera (injectable medroxyprogesterone acetate) is associated with a 53% increased risk of developing meningioma. The risk becomes significantly higher with prolonged use, reaching up to 5.55 times for women using it compared to non-users.
Q2. How does Depo-Provera potentially cause meningiomas? Depo-Provera may trigger meningioma growth through progesterone receptors, which are abundantly present in these tumors. The synthetic progestin in Depo-Provera can stimulate these receptors, potentially leading to tumor development, especially with long-term use.
Q3. Are there any warning labels about meningioma risk on Depo-Provera in the US? As of 2024, there are no specific warnings about meningioma risk on Depo-Provera labels in the United States. However, such warnings have been added to labels in Europe, Canada, and other countries, which has become a point of contention in ongoing lawsuits. This will be at issue in the Depo-Provera lawsuit.
Q4. Who might be eligible to file a Depo-Provera lawsuit? Individuals who have used Depo-Provera for at least one year, were diagnosed with meningioma at least three years after starting injections, and were 70 years old or younger at the time of diagnosis may be eligible to file a lawsuit. It’s best to consult with a specialized Depo-Provera Meningioma Lawyer in Nashville to determine eligibility.
Q5. What kind of compensation might be available in Depo-Provera lawsuit? Compensation in a Depo-Provera lawsuit may cover medical expenses, lost wages, pain and suffering, and compensation for permanent disability. Settlement estimates range from $100,000 to $500,000, with potentially higher amounts for severe cases involving multiple surgeries or permanent disabilities. For more information about compensation in a Depo-Provera lawsuit, contact a Nashville Depo-Provera Meningioma Lawyer.
If you have used Depo-Provera for at least one year, were diagnosed with meningioma at least three years after starting injections, and were 70 years old or younger at the time of diagnosis may be eligible to file a lawsuit.
Contact Nashville Depo-Provera Meningioma Lawyer Timothy L. Miles Today for a free case evaluation. The call is free and so is the fee, so call today and see what a Nashville Depo-Provera Meningioma Attorney can do for you. (855) 846-6529 or [email protected],
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com
DEPO-PROVERA MENINGIOMA LAWYER IN NASHVILLE
TIMOTHY L. MILES
(855) TIM-M-LAW (855-846-659)
(24/7/365)